Drug Discovery Services Market (By Process: Target Selection, Target Validation, Hit to Lead Identification, Lead Optimization, and Candidate Validation; By Drug Type: Biologics and Small Molecules; By Type: DMPK, Biology Services, and Medicinal Chemistry; By Therapeutic Area: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Respiratory Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Drug Discovery Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Drug Discovery Services Market, by Process Type, 2023-2032
8.1.1. Target Selection
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Target Validation
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Hit to Lead Identification
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Lead Optimization
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Candidate Validation
8.1.5.1. Market Revenue and Forecast (2020-2032)
9.1. Drug Discovery Services Market, by Drug Type, 2023-2032
9.1.1. Small Molecules
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Biologics
9.1.2.1. Market Revenue and Forecast (2020-2032)
10.1. Drug Discovery Services Market, by Type, 2023-2032
10.1.1. DMPK
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Biology Services
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Medicinal Chemistry
10.1.3.1. Market Revenue and Forecast (2020-2032)
11.1. Drug Discovery Services Market, by Therapeutic Area Type, 2023-2032
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Diabetes
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Neurology
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Respiratory Diseases
11.1.5.1. Market Revenue and Forecast (2020-2032)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2020-2032)
12.1. North America
12.1.1. Market Revenue and Forecast, by Process (2020-2032)
12.1.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.1.3. Market Revenue and Forecast, by Type (2020-2032)
12.1.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Process (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Process (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Process (2020-2032)
12.2.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.2.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Process (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Process (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Process (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Process (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Process (2020-2032)
12.3.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.3.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Process (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Process (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Process (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Process (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Process (2020-2032)
12.4.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.4.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Process (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Process (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Process (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Process (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Process (2020-2032)
12.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Process (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Process (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)
13.1. Abbott Laboratories Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Advinus Therapeutics
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Agilent Technologies Ubiquigent
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Albany Molecular Research Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca PLC
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Aurigene
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bayer AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Charles River Laboratories International
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. ChemBridge Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Covance
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample